Prevalence of Patients Receiving Urate-Lowering Medicine in Greenland and Denmark: A Cross-Sectional Case–Control Study

Sidsel Dan Hull, Marianne Welzel Andersen, Jessica Bengtsson, Nils Skovgaard, Marie Balslev Backe and Michael Lynge Pedersen
Additional contact information
Sidsel Dan Hull: Department of Public Heath, University of Copenhagen, 1353 Copenhagen, Denmark
Marianne Welzel Andersen: Queen Ingrid’s Hospital, Nuuk 3900, Greenland
Jessica Bengtsson: Department of Public Heath, University of Copenhagen, 1353 Copenhagen, Denmark
Nils Skovgaard: Queen Ingrid’s Hospital, Nuuk 3900, Greenland
Marie Balslev Backe: Steno Diabetes Center Greenland, Queen Ingrid’s Hospital, Nuuk 3900, Greenland
Michael Lynge Pedersen: Steno Diabetes Center Greenland, Queen Ingrid’s Hospital, Nuuk 3900, Greenland

IJERPH, 2022, vol. 19, issue 12, 1-8

Abstract: This study estimates the age- and sex-specific prevalence of patients receiving urate-lowering therapy (ULT) in Greenland and compares the results with estimates in Denmark. Characteristics of patients receiving ULT in Greenland were compared to age- and sex-matched controls. The study was designed as a cross-sectional case–control study based on nationwide data from medical and population registers in Greenland and Denmark. The prevalence of patients receiving ULT was significantly lower in Greenland (0.55%) compared to Denmark (1.40%) ( p < 0.001). In both countries, the prevalence increased with age and was higher among men compared to women. In Greenland, patients receiving ULT were more often overweight, and more frequently received blood glucose-, lipid-, and blood pressure-lowering medicine including diuretics compared to age- and sex-matched controls. The prevalence of patients receiving ULT was significantly lower in Greenland compared to Denmark. Common life-style related risk factors for hyperuricemia and gout were observed frequently among ULT-treated patients compared to controls. Along with an increasing prevalence of lifestyle-related diseases in Greenland, the prevalence of patients receiving ULT may increase in the years to come. More focus on detection and management of hyperuricemia and gout in Greenland is warranted to improve quality of health care.

Keywords: gout; allopurinol; febuxostat; Greenland; Denmark; prevalence (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/12/7247/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/12/7247/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:12:p:7247-:d:837920

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().